antiantibody
mapatumumab
vaxin
ocrelizumab
histocompatibility antigen
myelosclerosis
immunohistochemical
immunofluorohistochemistry
atezolizumab
-lim-
chromobody
RAT test
immunocompetent
antimouse
tabalumab
cytotoxic reaction
tislelizumab
cergutuzumab
recognition
teclistamab
pidilizumab
ravulizumab
specific
immunosynaptic
gevokizumab
polyvalent
affinity
antihistone
abagovomab
teprotumumab
brolucizumab
antiplasma
olaratumab
immunocytic
antigenic
ipilimumab
histoimmunochemical
idiospecific
-les-
autocentromere
-ab
iratumumab
preimmunoadsorption
immunoreactively
microlymphocytotoxicity
immunorepressive
reagin